British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback